U.S. markets closed

Acerus Pharmaceuticals Corporation (ASPCF)

Other OTC - Other OTC Delayed Price. Currency in USD
0.85000.0000 (0.00%)
At close: 12:01PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.8500
BidN/A x N/A
AskN/A x N/A
Day's Range0.8500 - 0.8500
52 Week Range0.0200 - 8.0000
Avg. Volume67
Market Cap7.4M
Beta (5Y Monthly)1.20
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ASPCF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    Daily – Vickers Top Buyers & Sellers for 12/05/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • GlobeNewswire

    Acerus Reports Third Quarter 2022 Financial Results

    TORONTO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three and nine-month period ended September 30, 2022. Unless otherwise noted, all amounts are in US dollars and are prepared in accordance with International Financial Reporting Standards (“IFRS”). Recent Highlights Total Natesto® prescriptions in the US rose 69% year-over-year in the third quarter of 2022 and were up appr

  • GlobeNewswire

    Acerus Announces Amendment to Promissory Note Due to Former Serenity Shareholders

    TORONTO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that it has amended the promissory note (the “Note”) in the amount of US$4.91 million related to the up-front fee owed to former Serenity Pharmaceuticals LLC (“Serenity”) securityholders. The securityholder representative and Acerus agreed that the amount of the note would be increased to US$7.75 million. Repayment of the Note would be done via a paymen

  • GlobeNewswire

    Acerus Announces Initiation of Strategic Review

    Ernst & Young Orenda Corporate Finance Inc. (“EY”) engaged as independent financial advisors TORONTO, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced that the Board of Directors has determined to undertake a strategic review of capital and business alternatives, including a possible debt or equity financing, asset sale, M&A, or licensing transaction. The Board has struck a committee of independent director